Jan Hillson
Directeur/Membre du Conseil chez ELEDON PHARMACEUTICALS, INC.
Fortune : - $ au 31/05/2024
Profil
Jan L.
Hillson is currently an Independent Director at Eledon Pharmaceuticals, Inc., Chief Medical Officer at GlycoEra AG, and a Partner at Cascadia Drug Development Group LLC.
Previously, Dr. Hillson held positions as a Medical Director at Xcyte Therapies, Inc., Senior Director at ZymoGenetics, Inc., Vice President-Clinical & Translational Research at Momenta Pharmaceuticals, Inc., Assistant Professor at the University of Washington, Division Head at Virginia Mason Medical Center, Senior Vice President-Drug Development at ChemoCentryx, Inc., and Member-Clinical Faculty at Harvard Medical School.
Dr. Hillson also served as a Senior Vice President-Clinical Development at Provention Bio, Inc. from 2021 to 2024 and at Alpine Immune Sciences, Inc. from 2019 to 2021.
Dr. Hillson's education includes an undergraduate degree from Michigan State University, a graduate degree from the California Institute of Technology and the Scripps Institution of Oceanography, and a doctorate from Stanford University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/05/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Jan Hillson
| Sociétés | Poste | Début |
|---|---|---|
| ELEDON PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 02/07/2021 |
GlycoEra AG
 GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Directeur Technique/Scientifique/R&D | 01/02/2024 |
Cascadia Drug Development Group LLC
 Cascadia Drug Development Group LLC Miscellaneous Commercial ServicesCommercial Services Cascadia Drug Development Group LLC is an American company that has well-qualified CDDG Affiliates. The private company is located in the US. The company's focus is not explicitly stated in the provided meta data, but it appears to be related to drug development. | Corporate Officer/Principal | 01/02/2024 |
Anciens postes connus de Jan Hillson
| Sociétés | Poste | Fin |
|---|---|---|
| PROVENTION BIO, INC. | Corporate Officer/Principal | 01/02/2024 |
| ALPINE IMMUNE SCIENCES, INC. | Directeur Technique/Scientifique/R&D | 01/11/2021 |
| CHEMOCENTRYX, INC. | Corporate Officer/Principal | 01/06/2019 |
| MOMENTA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2016 |
ZymoGenetics, Inc.
 ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | 01/01/2013 |
Formation de Jan Hillson
| Michigan State University | Undergraduate Degree |
| California Institute of Technology | Graduate Degree |
| Scripps Institution of Oceanography | Graduate Degree |
| Stanford University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ELEDON PHARMACEUTICALS, INC. | Health Technology |
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
| Xcyte Therapies, Inc. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
Virginia Mason Medical Center
 Virginia Mason Medical Center Medical/Nursing ServicesHealth Services Virginia Mason Medical Center provides healthcare services. It offers primary and cancer care, diabetes center, digestive disorders, heart care, neurology and neurosurgery, medicine, surgery, urology, and orthopedics and sports. The company was founded by James Tate Mason, John M. Blackford, and Maurice Dwyer in 1920 and is headquartered in Seattle, WA. | Health Services |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
GlycoEra AG
GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Health Technology |
Cascadia Drug Development Group LLC
Cascadia Drug Development Group LLC Miscellaneous Commercial ServicesCommercial Services Cascadia Drug Development Group LLC is an American company that has well-qualified CDDG Affiliates. The private company is located in the US. The company's focus is not explicitly stated in the provided meta data, but it appears to be related to drug development. | Commercial Services |
